- Home
- SOS vs BFRI Comparison
SOS vs BFRI Comparison
Compare SOS & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOS | BFRI |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 16.3M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOS | BFRI |
|---|---|---|
| Price | $0.36 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | ★ 2.5M | 729.6K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,705,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $0.29 | $0.57 |
| 52 Week High | $2.35 | $1.66 |
Technical Indicators
Market Signals| Indicator | SOS | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 26.88 | 40.85 |
| Support Level | N/A | $0.78 |
| Resistance Level | $1.10 | $1.66 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 7.95 | 13.64 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.